SubsidieMeestersAI-powered platform for autologous iPSC manufacturing
The project aims to develop an AI-guided microfluidic device for the standardized, cost-effective mass production of personalized iPSCs to enhance cancer therapies and tissue regeneration.
Projectdetails
Introduction
Induced pluripotent stem cells (iPSCs) can be differentiated into any cell type of the body and transplanted without rejection. The potential of iPSCs to cure health problems including degenerative diseases, cancer, cancer therapy associated diseases, and defective tissues is unprecedented in history.
Current Challenges
However, the current methodologies prohibit standardized production of a person's own (autologous) iPSCs, hence rejection is taking place and the therapeutic promise is not fulfilled.
Project Objectives
Our consortium seeks to develop a new technology that will enable the mass production of personalized iPSCs for:
- Autologous adoptive cancer immunotherapies
- Hematopoietic stem cell transplantation
- Tissue regeneration
Innovative Approach
The consortium will, for the first time, create an artificial intelligence (AI) guided microfluidic device that standardizes the GMP production of autologous iPSCs quickly and at a fraction of the current cost.
Research and Development
Moreover, it will conduct cutting-edge single-cell genomics and bioinformatics research of iPSCs to:
- Identify clones of the highest quality
- Develop a database that will be the basis for AI software to select clones that meet clinical standards
Consortium Expertise
The consortium comprises experts in:
- Microfluidics engineering
- Process automation for cell therapies
- Stem cell molecular biology and bioinformatics
- GMP production
- AI modeling
The participating companies, startups, and universities are among the leading in Europe and will promote the positions of female and early career participants from developed and developing European countries.
Goals and Future Plans
The consortium aims to reach TRL3 prototype stage and has created a concrete exploitation plan to develop the technology further for implementation in cancer therapy and regenerative medicine.
Conclusion
Altogether, we propose to create revolutionary technology for low-cost, fast, and standardized automated mass production of autologous iPSCs, which holds the potential to enable numerous new therapies and make them accessible to the public.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 3.999.225 |
| Totale projectbegroting | € 3.999.225 |
Tijdlijn
| Startdatum | 1-9-2022 |
| Einddatum | 31-8-2026 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- MIDA BIOTECH BVpenvoerder
- DEEPPATH MONOPROSOPI I.K.E
- UNIVERSITEIT LEIDEN
- MIRCOD
- BIT BIO DISCOVERY GMBH
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation. | EIC Pathfinder | € 2.996.550 | 2022 | Details |
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images. | EIC Pathfinder | € 2.744.300 | 2022 | Details |
Dynamic Spatio-Temporal Modulation of Light by Phononic ArchitecturesDynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements. | EIC Pathfinder | € 2.552.277 | 2022 | Details |
Emerging technologies for crystal-based gamma-ray light sourcesTECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology. | EIC Pathfinder | € 2.643.187 | 2022 | Details |
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"
The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation.
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.
The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images.
Dynamic Spatio-Temporal Modulation of Light by Phononic Architectures
Dynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements.
Emerging technologies for crystal-based gamma-ray light sources
TECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Dissecting the molecular regulation of hematopoietic stem cell emergence using pluripotent stem cells to improve ex vivo therapiesThis project aims to develop methods for generating and expanding hematopoietic stem cells from patient-specific induced pluripotent stem cells to overcome transplantation barriers and enhance therapies. | ERC COG | € 2.000.000 | 2023 | Details |
Paving the way for off-the-shelf adoptive Treg therapy using epigenetic forward programmingThis project aims to develop a novel method for creating off-the-shelf regulatory T cells from human induced pluripotent stem cells through epigenetic editing for therapeutic use. | ERC POC | € 150.000 | 2025 | Details |
Scaling up iPSC Expansion and Differentiation using Recombinant BioemulsionsThe project aims to develop scalable, regulatory-compliant bioemulsions using engineered protein nanosheets for efficient iPSC culture and differentiation, enhancing cell manufacturing and biotech market growth. | ERC POC | € 150.000 | 2025 | Details |
Rapid Interventional Stem cells Platform 2.0 (RISP)Dit project richt zich op de ontwikkeling en validatie van een modulair, op afstand bestuurbaar platform voor de veilige productie en kwaliteitscontrole van (stam)celproducten, met als doel wereldwijde distributie. | MIT R&D Samenwerking | € 180.430 | 2018 | Details |
Dissecting the molecular regulation of hematopoietic stem cell emergence using pluripotent stem cells to improve ex vivo therapies
This project aims to develop methods for generating and expanding hematopoietic stem cells from patient-specific induced pluripotent stem cells to overcome transplantation barriers and enhance therapies.
Paving the way for off-the-shelf adoptive Treg therapy using epigenetic forward programming
This project aims to develop a novel method for creating off-the-shelf regulatory T cells from human induced pluripotent stem cells through epigenetic editing for therapeutic use.
Scaling up iPSC Expansion and Differentiation using Recombinant Bioemulsions
The project aims to develop scalable, regulatory-compliant bioemulsions using engineered protein nanosheets for efficient iPSC culture and differentiation, enhancing cell manufacturing and biotech market growth.
Rapid Interventional Stem cells Platform 2.0 (RISP)
Dit project richt zich op de ontwikkeling en validatie van een modulair, op afstand bestuurbaar platform voor de veilige productie en kwaliteitscontrole van (stam)celproducten, met als doel wereldwijde distributie.